Clinical Trials Logo

Citation(s)

  •   Maris J, Minturn J, Evans A, et al
    : Phase I trial of the orally bioavailable TRK tyrosine kinase inhibitor CEP-701 in refractory neuroblastoma: a New Approaches to Neuroblastoma Therapy (NANT) study. [Abstract] Pediatr Blood Cancer 45 (4 Suppl 1): A-0.12
  •   Minturn JE, Villablanca J, Yanik GA, et al
    : Phase I trial of lestaurtinib for children with refractory neuroblastoma (NB): A New Approach to Neuroblastoma Therapy (NANT) Consortium study. [Abstract] J Clin Oncol 28 (Suppl 15): A-9532, 2010.

A Phase I Study Of CEP-701 In Patients With Refractory Neuroblastoma (IND # 67,722)

Details for clinical trial NCT00084422